New drug RAP-219 aims to tame manic episodes in bipolar i disorder

NCT ID NCT07046494

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 28 times

Summary

This study tests an investigational drug called RAP-219 for people with bipolar I disorder who are currently experiencing a manic episode. The goal is to see if RAP-219 can safely reduce manic symptoms compared to a placebo. About 250 participants will take either the drug or a placebo, and doctors will measure changes in mania severity using standard rating scales.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BIPOLAR 1 DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Arch Clinical Trials

    RECRUITING

    St Louis, Missouri, 63125, United States

    Contact

    Contact

  • CNRI - San Diego, LLC

    WITHDRAWN

    San Diego, California, 92123, United States

  • CenExel - Decatur

    RECRUITING

    Decatur, Georgia, 30030, United States

    Contact

    Contact

  • CenExel - Gaithersburg

    ACTIVE_NOT_RECRUITING

    Gaithersburg, Maryland, 20877, United States

  • CenExel - Hollywood

    RECRUITING

    Hollywood, Florida, 33024, United States

    Contact

    Contact

  • Collaborative Neuroscience Research - Los Alamitos

    RECRUITING

    Los Alamitos, California, 90720, United States

    Contact

    Contact

  • Community Clinical Research, Inc.

    RECRUITING

    Austin, Texas, 78754, United States

    Contact

    Contact

  • HD Research - Memorial Hermann Village

    RECRUITING

    Houston, Texas, 77043, United States

    Contact

    Contact

  • Inland Psychiatric Medical Group - Chino

    ACTIVE_NOT_RECRUITING

    Chino, California, 91710, United States

  • NRC Research Institute - Orange

    RECRUITING

    Orange, California, 92868, United States

    Contact

    Contact

  • NeuroBehavioral Hospitals of the Palm Beaches - South

    RECRUITING

    Boynton Beach, Florida, 33426, United States

    Contact

    Contact

  • Neuroscience Research Institute at Ambrosia

    RECRUITING

    West Palm Beach, Florida, 33407, United States

    Contact

    Contact

  • New Hope Clinical Research

    RECRUITING

    Charlotte, North Carolina, 28211, United States

    Contact

    Contact

  • Pillar Clinical Research - Chicago

    RECRUITING

    Chicago, Illinois, 60641, United States

    Contact

    Contact

  • Pillar Clinical Research - Little Rock

    RECRUITING

    Little Rock, Arkansas, 72204, United States

    Contact

    Contact

  • Pillar Clinical Research - Richardson

    ACTIVE_NOT_RECRUITING

    Richardson, Texas, 75080, United States

  • Richmond Behavioral Associates

    RECRUITING

    Staten Island, New York, 10314, United States

    Contact

    Contact

  • Segal Trials - Miami Lakes Medical Research Early Phase, Inpatient & Outpatient Site

    RECRUITING

    Miami Lakes, Florida, 33016, United States

    Contact

    Contact

  • Synergy Clinical Research Center - San Diego

    RECRUITING

    Lemon Grove, California, 91945, United States

    Contact

    Contact

  • United Research Institute

    RECRUITING

    Hialeah, Florida, 33012, United States

    Contact

    Contact

  • Woodland International Research Group

    WITHDRAWN

    Little Rock, Arkansas, 72211, United States

  • Woodland Research Northwest

    RECRUITING

    Rogers, Arkansas, 72758, United States

    Contact

    Contact

Conditions

Explore the condition pages connected to this study.